AGX Silver X Mining Corp

Agennix AG (FRANKFURT: AGX) (XETRA: AGX) today announced that data from the talactoferrin Phase 2 trial in severe sepsis will be presented at the upcoming International Conference of the American Thoracic Society (ATS) in New Orleans, LA. The presentation, which is entitled, "Talactoferrin Alfa Reduces Mortality in Severe Sepsis: Results of a Phase 2 Randomized, Placebo-Controlled Double-Blind Study," will be part of a mini-symposium, New Treatment Approaches for Lung Disease: Late Breaking Abstracts. The data will be presented at 9:45 AM CDT on Monday, May 17, 2010 by K. Guntupalli, M.D., Professor and Chief, Pulmonary Critical Care and Sleep Medicine, Baylor College of Medicine and principal investigator of the talactoferrin trial.

About Agennix Agennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients. The Company's most advanced program is talactoferrin, an oral therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase 2 studies in non-small cell lung cancer, as well as in severe sepsis. Talactoferrin is currently in Phase 3 clinical trials in non-small cell lung cancer, and Agennix plans to develop this program further for the treatment of severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Martinsried/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. There can be no guarantee that talactoferrin will be developed for severe sepsis in a timely manner, if at all, or that talactoferrin will ultimately be approved for sale in any country. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

For further information, please contact: Agennix AG Investor Relations & Corporate Communications Phone: +49 (0)89 8565 2693 ir@agennix.com In the U.S.: Laurie Doyle Director, Investor Relations & Corporate Communications Phone: +1 609 524 5884 laurie.doyle@agennix.com Additional media contacts for Europe: MC Services AG Phone: +49 (0) 89 210 228 0 Raimund Gabriel raimund.gabriel@mc-services.eu Hilda Juhasz hilda.juhasz@mc-services.eu Additional investor contact for Europe: Trout International LLC Lauren Williams, Vice President Phone: +44 207 936 9325 lwilliams@troutgroup.com